NCT03545789 is a Phase 1 clinical trial of [18F]MNI-958 in Healthy Volunteers, sponsored by Invicro.

Who is sponsoring NCT03545789?

NCT03545789 is sponsored by Invicro.

What drugs are being tested in NCT03545789?

Interventions in NCT03545789: [18F]MNI-958.

What condition does NCT03545789 study?

NCT03545789 studies Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy.

Is NCT03545789 still recruiting?

NCT03545789 is currently completed. Last updated 17 February 2020.

Last reviewed 2020-02-17 · How we verify

NCT03545789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

Completed Phase 1 Last updated 17 February 2020

What this trial tests

Phase 1 trial testing [18F]MNI-958 in Healthy Volunteers in 16 participants. Completed in 6 February 2020.

Timeline

12 March 2018

Primary endpoint
6 February 2020

6 February 2020

Quick facts

Lead sponsor	Invicro
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	16
Start date	12 March 2018
Primary completion	6 February 2020
Estimated completion	6 February 2020
Sites	1 location across United States

Drugs / interventions tested

[18F]MNI-958 — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →
Alzheimer Disease — all drugs for Alzheimer Disease →
Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →

Sponsor

Invicro — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal of this protocol is to evaluate \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective.
Ricci M, Cimini A, Camedda R, Chiaravalloti A, et al · · 2021 · cited 12× · PMID 34884804 · DOI 10.3390/ijms222313002

Verify or expand the search:

Other trials of [18F]MNI-958

Trials testing the same drug.

NCT03472313 — Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects · Phase 1 · completed
NCT03058965 — Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain · EARLY_PHASE1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Invicro trials

Trials by the same sponsor.

NCT05274568 — Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein · Phase 1 · completed
NCT05164536 — Plasma P-tau2017 and Quantitative Amyloid PET Imaging · Phase 1 · completed
NCT05009199 — Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444 · Phase 1 · completed
NCT05005819 — Evaluation of [18F]APN-1607 as a PET Biomarker · Phase 1 · completed
NCT06445465 — Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03545789 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Invicro
Last refreshed: 17 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03545789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing